Dr. Cathy Reback’s research is included in the SAMHSA intervention guide, “Prevention and Treatment of HIV among People Living with Substance Use and/or Mental Disorders.” The Alexis Project is a combined Peer Health Navigation (PHN) and Contingency Management (CM) intervention that targets HIV milestones associated with advancement along the HIV Care Continuum. Although designed for […]
Friends Research Institute (FRI) and its clinical collaborators at Chase Brexton Health Care are serving as one of the five sites in a National Institute of Drug Abuse (NIDA) Clinical Trials Network study, entitled the Subthreshold Opioid Use Disorder Prevention (STOP) trial. Research personnel at FRI will assist with the conduct of the study. The […]
FRI is pleased to announce that Dr. Ariel Ludwig has been promoted from a Research Associate to an Assistant Research Scientist, effective September 24, 2020. Since joining FRI in 2019, Dr. Ludwig has performed several qualitative analyses of research data resulting in publications ranging from the establishment of methodological best practices (in press, International Journal […]
FRI is proud to announce that Dr. Jan Gryczynski received the Most Reviewed Articles award (tied with two other reviewers) from the Journal of Addiction Medicine for peer reviewing nine papers for the Journal in 2019. This is the second time that Dr. Gryczynski has received this award. Click here to see article.
We are pleased to announce that Dr. Mishka Terplan has been promoted to serve as Associate Medical Director of Friends Research Institute. Dr. Terplan is board certified in both Obstetrics and Gynecology and Addiction Medicine. His primary research expertise lies along the intersections of reproductive and behavioral health. In addition to his work at FRI, […]
Drs. Michael Gordon, Timothy Kinlock (retired) and Robert Schwartz were cited in an April 2020 Pew Charitable Trusts report for their work on two National Institute on Drug Abuse (NIDA) funded studies involving the initiation of methadone and buprenorphine-naloxone with individuals who were currently in prison. This work was conducted in collaboration with the Maryland […]
FRI is pleased to announce that Dr. Mishka Terplan has accepted the position of Senior Physician Research Scientist at FRI. Dr. Terplan is a physician who is Board Certified in both Obstetrics & Gynecology and Addiction Medicine. His primary clinical, research and advocacy interests rest along the intersection of reproductive and behavioral health. He is […]
In July of 2019, the Baltimore Sun Editorial Board published an article entitled, “Maryland can stop black market suboxone in prisons by making it available to inmates.” The article cited two of Dr. Michael Gordon’s ongoing National Institute on Drug Abuse funded studies: (1) Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment; […]
FRI is pleased to announce that Dr. Thomas R. Blue has been promoted from an Assistant Research Scientist to a Research Scientist, effective July 17, 2019. Since joining FRI in 2017, Dr. Blue has performed several secondary analyses of research data including analyses of arrest outcomes (now published in the Journal of Drug and Alcohol Dependence) and […]
MAXINE L. STITZER, Ph.D. Professor Emerita of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine Dr. Stitzer was a founding faculty member of the Behavioral Pharmacology Research Unit, a nationally recognized substance abuse research laboratory within the Department of Psychiatry at Johns Hopkins School of Medicine. Her research interests during a successful 40+ year career […]
